Related Experiment Video
Updated: Jun 2, 2026

Whole Vitreous Humor Dissection for Vitreodynamic Analysis
Published on: May 24, 2015
Utility values associated with vitreous floaters
Ajeet M Wagle1, Wei-Yen Lim, Tiong-Peng Yap
1Department of Ophthalmology and Visual Sciences, Khoo Teck Puat Hospital, Singapore. wagle.ajeet.madhav@alexandrahealth.com.sg
Purpose:
To ascertain the health-related quality of life associated with symptomatic degenerative vitreous floaters.
Design:
Cross-sectional questionnaire survey.
Methods:
In this institution-based study, 311 outpatients aged 21 years and older who presented with symptoms of floaters were enrolled. Data from 266 patients (85.5%) who completed the questionnaire were analyzed. Utility values were assessed using a standardized utility value questionnaire. The time trade-off (TTO) and standard gamble (SG) for death and blindness techniques were used to calculate the utility values. Descriptive, univariate, and multivariate analyses were performed using Stata Release 6.0.
Results:
The mean age of the study population was 52.9 ± 12.02 years (range, 21-97). The mean utility values were 0.89, 0.89, and 0.93 for TTO, SG (death), and SG (blindness), respectively. Patients aged ≤55 years reported significantly lower SG (blindness) utility values when compared with patients above 55 years of age (age ≤55 = 0.92, age >55 = 0.94, P = .007). Utility measurements did not demonstrate significant relationship with any of the other socio-demographic variables examined in this study. The utility values did not demonstrate any significant relationship with other ocular characteristics such as duration of symptoms, presence of a posterior vitreous detachment, and presence or severity of myopia.
Conclusions:
Symptomatic degenerative vitreous floaters have a negative impact on health-related quality of life. Younger symptomatic patients are more likely to take a risk of blindness to get rid of the floaters than older patients.
Related Concept Videos
Glaucoma: Overview
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Photoreceptors and Visual Pathways
Angle Closure Glaucoma: Treatment

